Josh Schimmer

Sep 14, 2026

Josh Schimmer rated FDMT as Overweight on Sep 14, 2026, setting a price target of 20. Shares have remained stable near 13.17, leaving the 20 target still in play.

Jul 31, 2026

On Jul 31, 2026, NBIX was given a Overweight rating by Josh Schimmer, with a target price of 215. Despite the Buy call, shares fell from 156.22 to 156.22, challenging the optimistic stance.

Jun 22, 2026

INSM received a Outperform rating from Josh Schimmer on Jun 22, 2026, aiming for 160. Momentum has favored the Buy call, with shares climbing from 129.41 to 129.41, rewarding those who trusted the recommendation.

May 28, 2026

On May 28, 2026, Josh Schimmer published a Overweight outlook on SPRY, with a target of 30. Market action contradicted the Buy thesis, as shares slipped to 4.76.

May 15, 2026

Josh Schimmer on May 15, 2026 assigned ASND a Outperform rating, with a price target of 329. The Buy call aligned well with market performance, producing a gain of 9.57%.

May 11, 2026

On May 11, 2026, Josh Schimmer reaffirmed ARTV with a Overweight rating, targeting 40. Market indecision has kept the 40 target in a holding pattern.

May 04, 2026

CABA was rated Overweight by Josh Schimmer on May 04, 2026, with a price objective of 30. This case shows how bullish projections can fail, with the stock now below 2.73.

Feb 27, 2026

On Feb 27, 2026, Josh Schimmer initiated coverage on NUVL with a Overweight rating and target of 140. The stock’s climb of 21.59% since the call highlights the foresight in the rating.

Feb 27, 2026

Josh Schimmer issued a Overweight recommendation for RCKT on Feb 27, 2026, price target set at 10. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Feb 27, 2026

On Feb 27, 2026, JANX was evaluated by Josh Schimmer, who gave a Overweight rating and target of 150. This case illustrates how a timely bullish rating can translate into tangible gains of 25.64%.

Nov 14, 2025

Josh Schimmer rated DMAC as Overweight on Nov 14, 2025, setting a price target of 25. The call has proven timely, with shares rising 9.11% toward the price target of 25.

Nov 06, 2025

On Nov 06, 2025, PVLA was given a Overweight rating by Josh Schimmer, with a target price of 200. The stock rallied 90.93% after the rating, narrowing the gap to the target of 200 and validating the bullish stance.

Nov 05, 2025

MIRM received a Overweight rating from Josh Schimmer on Nov 05, 2025, aiming for 95. Momentum has favored the Buy call, with shares climbing from 98.22 to 98.22, rewarding those who trusted the recommendation.

Oct 30, 2025

On Oct 30, 2025, Josh Schimmer published a Overweight outlook on BBIO, with a target of 110. Shares gained 14.31%, underscoring the accuracy of the bullish outlook toward 110.

Oct 29, 2025

Josh Schimmer on Oct 29, 2025 assigned TRML a Overweight rating, with a price target of null. The recommendation remains pending validation as shares consolidate around 47.98.

Oct 06, 2025

On Oct 06, 2025, Josh Schimmer reaffirmed IVVD with a Overweight rating, targeting 10. Shares slid 44.68% despite the recommendation, highlighting downside risks.

Sep 22, 2025

RNA was rated Outperform by Josh Schimmer on Sep 22, 2025, with a price objective of 65. This case shows how bullish projections can fail, with the stock now below 10.36.

Sep 08, 2025

On Sep 08, 2025, Josh Schimmer initiated coverage on DNLI with a Overweight rating and target of null. The stock’s climb of 36.06% since the call highlights the foresight in the rating.

Sep 08, 2025

Josh Schimmer issued a Overweight recommendation for CGON on Sep 08, 2025, price target set at 75. Investors following the Buy call captured upside momentum, with shares now at 72.35.

Sep 05, 2025

On Sep 05, 2025, SEPN was evaluated by Josh Schimmer, who gave a Overweight rating and target of 25. This case illustrates how a timely bullish rating can translate into tangible gains of 166.87%.

Jul 01, 2025

Josh Schimmer rated TRVI as Overweight on Jul 01, 2025, setting a price target of 25. The call has proven timely, with shares rising 178.95% toward the price target of 25.

Apr 01, 2025

AARD received a Overweight rating from Josh Schimmer on Apr 01, 2025, aiming for 50. The rating hasn’t played out as hoped, with the stock trading 38.12% below expectations.

Feb 20, 2025

On Feb 20, 2025, Josh Schimmer published a Overweight outlook on KRYS, with a target of 215. Shares gained 90.01%, underscoring the accuracy of the bullish outlook toward 215.

Dec 11, 2024

On Dec 11, 2024, Josh Schimmer reaffirmed ZURA with a Overweight rating, targeting null. The recommendation was supported by strong follow-through as the stock rose from 5.21 to 5.21.

Sep 17, 2024

On Sep 17, 2024, Josh Schimmer initiated coverage on ALEC with a Overweight rating and target of null. The Buy call has yet to be validated as shares remain -2.14 away from the target.

Sep 16, 2024

Josh Schimmer issued a Overweight recommendation for CRNX on Sep 16, 2024, price target set at 90. Investors following the Buy call captured upside momentum, with shares now at 84.95.

Sep 09, 2024

On Sep 09, 2024, ARWR was evaluated by Josh Schimmer, who gave a Overweight rating and target of null. This case illustrates how a timely bullish rating can translate into tangible gains of 280.74%.

Sep 09, 2024

Josh Schimmer rated JSPR as Overweight on Sep 09, 2024, setting a price target of null. The stock has underperformed, dropping 96.58% despite the bullish target of null.

Sep 09, 2024

On Sep 09, 2024, ANNX was given a Overweight rating by Josh Schimmer, with a target price of null. Despite the Buy call, shares fell from 3.94 to 3.94, challenging the optimistic stance.

Sep 09, 2024

ARCT received a Overweight rating from Josh Schimmer on Sep 09, 2024, aiming for null. The rating hasn’t played out as hoped, with the stock trading 22.47% below expectations.

Aug 26, 2024

On Aug 26, 2024, Josh Schimmer published a Outperform outlook on RLYB, with a target of 15. Shares gained 85.03%, underscoring the accuracy of the bullish outlook toward 15.